An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 30 Nov 2013 New trial record
- 22 Nov 2013 Status changed from recruiting to completed.
- 25 Sep 2013 Status changed from not yet recruiting to recruiting.